The star of 'The Boys' and 'Companion' takes an '80s-style hero turn in his new action flick, where he plays a man who can't feel pain. "It’s not about how much I can kick a**," he says. "It’s about how much my a** can get kicked.

Paramount’s action comedy Novocaine saw the brilliant Jack Quaid continue his strong 2025 run, following the late-January release of the widely acclaimed sci-fi thriller, Companion. Having just debuted in theaters across the most recent weekend,

Jack Quaid’s action-comedy “ Novocaine ” topped a painfully slow weekend at the box office with $8.7 million. For theater owners, however, there’s not too much to celebrate: It’s one of the worst debuts to still capture the No. 1 spot (at least since the pandemic ground moviegoing to a halt).

March 2025 was never going to be huge at the domestic box office. While this time last year saw the movie release calendar populated with titles including Denis Villeneuve's Dune: Part Two, Mike Mitchell's Kung Fu Panda 4,

Novocaine could have been written by a 12-year-old, and I’m not sure I mean that pejoratively. It’s a riff on superhero stories, but it’s been thought up with a whiff of dopey plausibility: The film’s protagonist,

Quaid's leading role in Novocaine feels like a natural continuation of these genre-bent everymen. He plays Nathan Caine, a mild-mannered assistant bank manager who has congenital insensitivity to pain with anhidrosis (CIPA), a genetic disorder that impacts his nervous system to the point that he can't feel pain or temperature.

“Novocaine” only cost $18 million to produce, so (like its main character) it shouldn’t be feeling any pain at the box office. On the flip side, “Mickey 17” cost $118 million to produce and needs around $275 million to $300 million worldwide to make a profit.

Jack Quaid's action comedy film is looking to dethrone Mickey 17 at what might be the year's softest weekend at the box office so far.